Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

INTRODUCTION: Brentuximab vedotin (SGN-35), an anti-cluster of differentiation (CD)-30 antibody conjugated to the anti-tubulin agent monomethyl auristatin E, has demonstrated promising efficacy and tolerability in relapsed and heavily treated Hodgkin lymphoma (HL). In this study, we report the Asian...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yang, Qing-Ming, Hong, Jung Yong, Ko, Young Hyeh, Lin, Shek-Ying, Au, Wing-Yan, Choi, Moon Ki, Park, Silvia, Kim, Seok Jin, Kim, Won Seog
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2014
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196794/
https://ncbi.nlm.nih.gov/pubmed/25328405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S67380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados